| scholarly article | Q13442814 |
| P50 | author | Clara Lubeseder-Martellato | Q28656550 |
| Maria Sibilia | Q41133496 | ||
| David W. Threadgill | Q42306006 | ||
| Pawel K Mazur | Q42408768 | ||
| Barbara M Grüner | Q58212259 | ||
| Debjani Pal | Q63952964 | ||
| P2093 | author name string | Roland M Schmid | |
| Elaine W Raines | |||
| M Kay Washington | |||
| Carole L Wilson | |||
| Peter Storz | |||
| Bence Sipos | |||
| Howard C Crawford | |||
| Christopher J Halbrook | |||
| Eileen S Carpenter | |||
| Jason C Hall | |||
| Kenneth K Takeuchi | |||
| Nicole R Murray | |||
| Alexander Herner | |||
| Jens T Siveke | |||
| Nicole Teichmann | |||
| Marija Trajkovic-Arsic | |||
| Geou-Yarh Liou | |||
| Christine M Ardito | |||
| Kathleen E Delgiorno | |||
| Thomas Briel | |||
| P2860 | cites work | The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors | Q24304941 |
| Activation of the epidermal growth factor receptor by respiratory syncytial virus results in increased inflammation and delayed apoptosis | Q24314721 | ||
| RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer | Q27657185 | ||
| Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors | Q28291740 | ||
| Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras | Q29617087 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse | Q29620396 | ||
| Adam17-dependent shedding limits early neutrophil influx but does not alter early monocyte recruitment to inflammatory sites | Q30425907 | ||
| Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands | Q30443463 | ||
| Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice | Q33604913 | ||
| Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src. | Q33861952 | ||
| Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras | Q34082522 | ||
| Expression of oncogenic K-ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cells | Q34101151 | ||
| Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer | Q34332170 | ||
| Chronic pancreatitis is associated with increased concentrations of epidermal growth factor receptor, transforming growth factor alpha, and phospholipase C gamma | Q34379846 | ||
| Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse | Q34596182 | ||
| Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras | Q34620985 | ||
| The EGF receptor is required for efficient liver regeneration | Q36089334 | ||
| Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells | Q36098160 | ||
| Autocrine, paracrine and juxtacrine signaling by EGFR ligands | Q36176790 | ||
| Epidermal growth factor receptor (EGFR) signaling in cancer | Q36353031 | ||
| In vivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasia | Q36478584 | ||
| Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy | Q37127423 | ||
| Ras activity levels control the development of pancreatic diseases. | Q39841946 | ||
| In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas | Q40124759 | ||
| Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma | Q40230508 | ||
| Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines | Q40296336 | ||
| Role of epidermal growth factor receptor signaling in RAS-driven melanoma | Q40427048 | ||
| Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum | Q40442891 | ||
| A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells | Q41098690 | ||
| Role of Shc in the activation of Ras in response to epidermal growth factor and nerve growth factor | Q41415847 | ||
| Pancreatic acinar cells in culture: expression of acinar and ductal antigens in a growth-related manner | Q41970191 | ||
| Targeted disruption of the epidermal growth factor receptor impairs growth of squamous papillomas expressing the v-ras(Ha) oncogene but does not block in vitro keratinocyte responses to oncogenic ras. | Q42442094 | ||
| Early requirement of Rac1 in a mouse model of pancreatic cancer. | Q42490195 | ||
| The epidermal growth factor receptor is required to maintain the proliferative population in the basal compartment of epidermal tumors. | Q42491077 | ||
| The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development | Q42492007 | ||
| Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence | Q42573716 | ||
| EGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivo | Q44238991 | ||
| Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. | Q44396191 | ||
| Generation and validation of mice carrying a conditional allele of the epidermal growth factor receptor | Q46179704 | ||
| Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer | Q46643661 | ||
| Measuring Ras-family GTP levels in vivo--running hot and cold | Q46805883 | ||
| Overexpression of heparin-binding EGF-like growth factor in mouse pancreas results in fibrosis and epithelial metaplasia | Q47997951 | ||
| Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. | Q53329413 | ||
| Epiregulin Is Up-Regulated in Pancreatic Cancer and Stimulates Pancreatic Cancer Cell Growth | Q57767954 | ||
| Chronic Pancreatitis Is Essential for Induction of Pancreatic Ductal Adenocarcinoma by K-Ras Oncogenes in Adult Mice | Q61776577 | ||
| Overexpression of TGFα in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast | Q67660860 | ||
| Duct changes and K-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution | Q73258134 | ||
| Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis | Q73614651 | ||
| The homeodomain protein IDX-1 increases after an early burst of proliferation during pancreatic regeneration | Q74607806 | ||
| Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis | Q78962304 | ||
| Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates | Q80378426 | ||
| P433 | issue | 3 | |
| P921 | main subject | Kirsten rat sarcoma viral oncogene homolog | Q21498354 |
| Epidermal growth factor receptor | Q21981692 | ||
| P304 | page(s) | 304-317 | |
| P577 | publication date | 2012-09-01 | |
| P1433 | published in | Cancer Cell | Q280018 |
| P1476 | title | EGF receptor is required for KRAS-induced pancreatic tumorigenesis | |
| P478 | volume | 22 |
| Q36140634 | A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells |
| Q36437111 | A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma |
| Q37744279 | A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer |
| Q37488746 | A modular and flexible ESC-based mouse model of pancreatic cancer. |
| Q38902585 | A novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy. |
| Q59339787 | A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases |
| Q44709167 | A rapid ex vivo tissue model for optimising drug detection and ionisation in MALDI imaging studies. |
| Q38882024 | A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion |
| Q53224745 | A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. |
| Q37052477 | ADAM Proteases and Gastrointestinal Function |
| Q59137239 | ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy |
| Q64067287 | ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer |
| Q89721924 | ADAM17 stabilizes its interacting partner inactive Rhomboid 2 (iRhom2) but not inactive Rhomboid 1 (iRhom1) |
| Q92783310 | ADAM17: An Emerging Therapeutic Target for Lung Cancer |
| Q27324447 | ADAM8 as a drug target in pancreatic cancer. |
| Q61799832 | ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma |
| Q47661281 | ANO9/TMEM16J promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer. |
| Q91711463 | ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis |
| Q36710531 | Ablation of sensory neurons in a genetic model of pancreatic ductal adenocarcinoma slows initiation and progression of cancer |
| Q38922230 | Acinar cell plasticity and development of pancreatic ductal adenocarcinoma |
| Q43491732 | Activating transcription factor 3 promotes loss of the acinar cell phenotype in response to cerulein-induced pancreatitis in mice. |
| Q35136815 | Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies |
| Q96136047 | An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development |
| Q37628092 | Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas |
| Q54118277 | Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. |
| Q36017810 | Animal Models of Gastrointestinal and Liver Diseases. The difficulty of animal modeling of pancreatic cancer for preclinical evaluation of therapeutics |
| Q36169365 | Anterior Gradient 2 (AGR2) Induced Epidermal Growth Factor Receptor (EGFR) Signaling Is Essential for Murine Pancreatitis-Associated Tissue Regeneration |
| Q47098844 | Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma |
| Q33933185 | Areca nut components affect COX-2, cyclin B1/cdc25C and keratin expression, PGE2 production in keratinocyte is related to reactive oxygen species, CYP1A1, Src, EGFR and Ras signaling. |
| Q89520977 | CA19-9 as a therapeutic target in pancreatitis |
| Q39140268 | Canonical wnt signaling is required for pancreatic carcinogenesis |
| Q90566625 | Carcinogenesis of Pancreatic Ductal Adenocarcinoma |
| Q36801167 | Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer |
| Q33816883 | Cholecystokinin and pancreatic cancer: the chicken or the egg? |
| Q48212640 | Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibition. |
| Q35095399 | Coexpression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma |
| Q92379393 | Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status |
| Q37123636 | Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma |
| Q35677885 | Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer. |
| Q37686308 | Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface |
| Q90671653 | Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models |
| Q64256027 | Constitutive activation of EGFR is associated with tumor progression and plays a prominent role in malignant phenotype of chondrosarcoma |
| Q33910221 | Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis |
| Q35158112 | Development of a 'mouse and human cross-reactive' affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy. |
| Q91595228 | Differential impact of the ERBB receptors EGFR and ERBB2 on the initiation of precursor lesions of pancreatic ductal adenocarcinoma |
| Q38911598 | Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design |
| Q34246014 | Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma |
| Q33416585 | Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotini |
| Q36273532 | Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype |
| Q58550279 | EGFR is required for FOS-dependent bone tumor development via RSK2/CREB signaling |
| Q92669175 | EGFR, but not COX-2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival |
| Q42109581 | EGFR-induced phosphorylation of type Iγ phosphatidylinositol phosphate kinase promotes pancreatic cancer progression |
| Q37704531 | EGFR/ARF6 regulation of Hh signalling stimulates oncogenic Ras tumour overgrowth |
| Q52357887 | ETV5 regulates ductal morphogenesis with Sox9 and is critical for regeneration from pancreatitis. |
| Q41291488 | Elasticity mapping of murine abdominal organs in vivo using harmonic motion imaging (HMI). |
| Q24627664 | Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma |
| Q64119241 | Encircling the regions of the pharmacogenomic landscape that determine drug response |
| Q38844551 | Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells |
| Q92068202 | Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles |
| Q28084034 | Epidermal growth factor signaling in transformed cells |
| Q47121552 | Epithelial-Myeloid cell crosstalk regulates acinar cell plasticity and pancreatic remodeling in mice. |
| Q38389298 | ErbB-targeted CAR T-cell immunotherapy of cancer |
| Q42339289 | FAM83A is amplified and promotes cancer stem cell-like traits and chemoresistance in pancreatic cancer |
| Q45234060 | GRP78 haploinsufficiency suppresses acinar-to-ductal metaplasia, signaling, and mutant Kras-driven pancreatic tumorigenesis in mice |
| Q38798496 | GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression |
| Q41709484 | Gemcitabine-induced heparanase promotes aggressiveness of pancreatic cancer cells via activating EGFR signaling. |
| Q31066570 | Gene expression profile analysis of pancreatic cancer based on microarray data |
| Q37343012 | Genetic ablation of Smoothened in pancreatic fibroblasts increases acinar-ductal metaplasia. |
| Q34657038 | Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine |
| Q21129230 | Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma |
| Q53249482 | Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis. |
| Q88688533 | Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets |
| Q27002973 | Genetically engineered mouse models of pancreatic adenocarcinoma |
| Q26765438 | Genetics and biology of pancreatic ductal adenocarcinoma |
| Q89520937 | Glycosylation alterations in acute pancreatitis and pancreatic cancer: CA19-9 expression is involved in pathogenesis and maybe targeted by therapy |
| Q41966212 | Heparin-binding epidermal growth factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia. |
| Q90814722 | Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation |
| Q92917425 | Hiding in plain sight |
| Q58726181 | Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance |
| Q90465494 | ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer |
| Q42056219 | IL27 controls skin tumorigenesis via accumulation of ETAR-positive CD11b cells in the pre-malignant skin |
| Q41770555 | Identification and manipulation of biliary metaplasia in pancreatic tumors. |
| Q41856856 | Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma |
| Q38713554 | Identification of stable housekeeping genes in response to ionizing radiation in cancer research |
| Q55384914 | Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab). |
| Q33779491 | Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene |
| Q55252335 | In vivo reprogramming drives Kras-induced cancer development. |
| Q33727657 | Inflammation to cancer: The molecular biology in the pancreas (Review). |
| Q39008845 | Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. |
| Q36092073 | Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug. |
| Q52723252 | Integrated analysis of tumor differentiation genes in pancreatic adenocarcinoma. |
| Q28504893 | Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance |
| Q36068611 | K-Ras and cyclooxygenase-2 coactivation augments intraductal papillary mucinous neoplasm and Notch1 mimicking human pancreas lesions |
| Q43083283 | KRAS above and beyond - EGFR in pancreatic cancer |
| Q33566777 | KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents |
| Q37673906 | KRas, ROS and the initiation of pancreatic cancer |
| Q34659332 | Kras as a key oncogene and therapeutic target in pancreatic cancer |
| Q40291371 | Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells |
| Q47754576 | Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells. |
| Q36546501 | Loss of p27Kip¹ promotes metaplasia in the pancreas via the regulation of Sox9 expression |
| Q34861855 | Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition. |
| Q47246517 | Luteolin inhibits pancreatitis‑induced acinar‑ductal metaplasia, proliferation and epithelial‑mesenchymal transition of acinar cells. |
| Q33680759 | MAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice |
| Q51689102 | MET signaling in keratinocytes activates EGFR and initiates squamous carcinogenesis. |
| Q64100823 | MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC) |
| Q37071752 | Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs. |
| Q34283475 | Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors |
| Q36887721 | Mechanisms of resistance to EGFR targeted therapies |
| Q26827387 | Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells |
| Q99710192 | Metabolic regulation of EGFR effector and feedback signaling in pancreatic cancer cells requires K-Ras |
| Q41111798 | Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer |
| Q37699563 | Mitochondrial and Oxidative Stress-Mediated Activation of Protein Kinase D1 and Its Importance in Pancreatic Cancer |
| Q37585776 | Mitogen-activated Protein Kinase Kinase Activity Maintains Acinar-to-Ductal Metaplasia and Is Required for Organ Regeneration in Pancreatitis |
| Q26765241 | Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer |
| Q33624574 | Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward |
| Q38370174 | Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer |
| Q26798453 | Molecular Targeted Intervention for Pancreatic Cancer |
| Q46277416 | Molecular genetics and cellular events of K-Ras-driven tumorigenesis. |
| Q38211357 | Molecular mechanisms of oncogene-induced inflammation and inflammation-sustained oncogene activation in gastrointestinal tumors: an under-appreciated symbiotic relationship |
| Q26774636 | Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies |
| Q26751709 | Molecular therapeutics in pancreas cancer |
| Q92134380 | Mucin-1 is required for Coxsackie Virus B3-induced inflammation in pancreatitis |
| Q34943207 | Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions |
| Q34517052 | Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions |
| Q49788157 | Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. |
| Q92271692 | Myeloid Cell-Derived HB-EGF Drives Tissue Recovery After Pancreatitis |
| Q37600068 | Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer |
| Q38916311 | NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar-Ductal Transdifferentiation in the Pancreas. |
| Q36367008 | NFATc4 Regulates Sox9 Gene Expression in Acinar Cell Plasticity and Pancreatic Cancer Initiation |
| Q42330675 | NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer |
| Q30699331 | Neuropilin-2 Regulates Endosome Maturation and EGFR Trafficking to Support Cancer Cell Pathobiology |
| Q26765238 | Neutrophil-Derived Proteases in the Microenvironment of Pancreatic Cancer -Active Players in Tumor Progression |
| Q46948614 | New role of endoplasmic reticulum chaperones in regulating metaplasia during tumorigenesis. |
| Q35651453 | New targeted therapies in pancreatic cancer |
| Q91943325 | Noninvasive Young's modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elastography (HME) in vivo |
| Q38094850 | Notch signaling in pancreatic cancer: oncogene or tumor suppressor? |
| Q37582004 | Oncogenic K-Ras requires activation for enhanced activity |
| Q51049205 | Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis-A connection to licensing nodes. |
| Q34113460 | Oncogenic KRAS signalling in pancreatic cancer |
| Q42330768 | Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic Lesions |
| Q93167473 | Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer |
| Q99548635 | Organotypic Culture of Acinar Cells for the Study of Pancreatic Cancer Initiation |
| Q87195787 | Orthotopic inflammation-related pancreatic carcinogenesis in a wild-type mouse induced by combined application of caerulein and dimethylbenzanthracene |
| Q34616196 | PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice |
| Q38537351 | PLCε signaling in cancer |
| Q90371583 | PRDM3 attenuates pancreatitis and pancreatic tumorigenesis by regulating inflammatory response |
| Q92078077 | PYK2 Is Involved in Premalignant Acinar Cell Reprogramming and Pancreatic Ductal Adenocarcinoma Maintenance by Phosphorylating β-CateninY654 |
| Q26743482 | Pancreatic Cancer from Molecular Pathways to Treatment Opinion |
| Q55104265 | Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. |
| Q34590266 | Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α |
| Q92504704 | Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches |
| Q43207276 | Pancreatic oncogenic signaling cascades converge at Protein Kinase D1. |
| Q37589374 | Pathogenesis of pancreatic cancer: lessons from animal models |
| Q26797248 | Perspectives in the treatment of pancreatic adenocarcinoma |
| Q37721562 | Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study |
| Q37059925 | Phospho-Aspirin (MDC-22) Prevents Pancreatic Carcinogenesis in Mice |
| Q90425919 | Plasticity of differentiated cells in wound repair and tumorigenesis, part I: stomach and pancreas |
| Q38970683 | Polarization of the vacuolar adenosine triphosphatase delineates a transition to high-grade pancreatic intraepithelial neoplasm lesions |
| Q59801795 | Prolyl hydroxylase domain 3 influences the radiotherapy efficacy of pancreatic cancer cells by targeting hypoxia-inducible factor-1α |
| Q26801854 | Protein kinase D enzymes: novel kinase targets in pancreatic cancer |
| Q38409707 | Proteomic Identification of Cysteine Cathepsin Substrates Shed from the Surface of Cancer Cells. |
| Q93035794 | Putting the Cell of Origin for Pancreatic Cancer Into its Proper Context |
| Q96302844 | RAS-targeted therapies: is the undruggable drugged? |
| Q34786650 | RGS16, a novel p53 and pRb cross-talk candidate inhibits migration and invasion of pancreatic cancer cells |
| Q33906704 | Racial disparity in metabolic regulation of cancer |
| Q93013397 | RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer |
| Q36299502 | RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth |
| Q35071666 | Regeneration and repair of the exocrine pancreas |
| Q28086849 | Regulation of Cellular Identity in Cancer |
| Q38815948 | Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells. |
| Q42153632 | RelA: a tale of a stitch in time |
| Q38831157 | Relationship Between the Expression of O6-Methylguanine-DNA Methyltransferase (MGMT) and p53, and the Clinical Response in Metastatic Pancreatic Adenocarcinoma Treated with FOLFIRINOX. |
| Q26801731 | Reserve stem cells: Differentiated cells reprogram to fuel repair, metaplasia, and neoplasia in the adult gastrointestinal tract |
| Q39455125 | Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis |
| Q27693345 | Role of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective. |
| Q89475388 | Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer |
| Q38102106 | Roles for KRAS in pancreatic tumor development and progression |
| Q41959768 | SMAD4 loss enables EGF, TGFβ1 and S100A8/A9 induced activation of critical pathways to invasion in human pancreatic adenocarcinoma cells |
| Q53229089 | SOX9 regulates ERBB signalling in pancreatic cancer development. |
| Q104111327 | Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis |
| Q64274365 | Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers |
| Q64890448 | Signaling Networks That Control Cellular Plasticity in Pancreatic Tumorigenesis, Progression, and Metastasis. |
| Q27334054 | Silencing Mist1 Gene Expression Is Essential for Recovery from Acute Pancreatitis |
| Q34410212 | Smarter drugs emerging in pancreatic cancer therapy |
| Q89903812 | Substrate-selective protein ectodomain shedding by ADAM17 and iRhom2 depends on their juxtamembrane and transmembrane domains |
| Q37448070 | Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer |
| Q34123782 | TACE/ADAM17 is essential for oligodendrocyte development and CNS myelination |
| Q91620971 | TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis |
| Q38785433 | TIMPs: versatile extracellular regulators in cancer |
| Q38656693 | TIP30: A Novel Tumor-Suppressor Gene |
| Q92641653 | TMEM16A controls EGF-induced calcium signaling implicated in pancreatic cancer prognosis |
| Q90080150 | Targeting Autophagy by MPT0L145, a Highly Potent PIK3C3 Inhibitor, Provides Synergistic Interaction to Targeted or Chemotherapeutic Agents in Cancer Cells |
| Q37215991 | Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer |
| Q48907560 | Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer. |
| Q39007517 | Targeting reactive oxygen species in development and progression of pancreatic cancer |
| Q92152171 | The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer |
| Q39206028 | The Drosophila Chmp1 protein determines wing cell fate through regulation of epidermal growth factor receptor signaling |
| Q56929860 | The ERBB network facilitates KRAS-driven lung tumorigenesis |
| Q37271741 | The PRKD1 promoter is a target of the KRas-NF-κB pathway in pancreatic cancer |
| Q26765230 | The Significance of Ras Activity in Pancreatic Cancer Initiation |
| Q93081350 | The Use of Genetically Engineered Mouse Models for Studying the Function of Mutated Driver Genes in Pancreatic Cancer |
| Q35954277 | The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma |
| Q38919135 | The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice |
| Q34915977 | The conspiracy of autophagy, stress and inflammation in acute pancreatitis |
| Q41593158 | The crosstalk between acinar cells with Kras mutations and M1-polarized macrophages leads to initiation of pancreatic precancerous lesions |
| Q92917519 | The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice |
| Q38989132 | The impact of hypoxia in pancreatic cancer invasion and metastasis. |
| Q33725976 | The quest to overcome resistance to EGFR-targeted therapies in cancer |
| Q33827679 | The secret origins and surprising fates of pancreas tumors |
| Q38860417 | The sorting protein PACS-2 promotes ErbB signalling by regulating recycling of the metalloproteinase ADAM17. |
| Q36296335 | Tissue-specific tumorigenesis: context matters |
| Q92325200 | Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRASG13D mutation |
| Q34067863 | Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts |
| Q34364766 | Tumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote pancreatic adenocarcinoma |
| Q92188206 | Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer |
| Q87411406 | Tumorigenesis: Pushing pancreatic cancer to take off |
| Q28083091 | Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models |
| Q91816092 | Vav1 and mutant K-Ras synergize in the early development of pancreatic ductal adenocarcinoma in mice |
| Q34375528 | microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions |
| Q34123654 | pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104 |
| Q97534390 | κB-Ras and Ral GTPases regulate acinar to ductal metaplasia during pancreatic adenocarcinoma development and pancreatitis |
Search more.